阿帕替尼联合托泊替康治疗晚期铂类耐药复发卵巢癌的临床研究  

Clinical study of apatinib combined with topotecan in the treatment of advanced platinum-resistant relapsed ovarian cancer

作　　者：司晓燕[1] 卢辉[1] SI Xiao-yan;LU Hui(Department of Oncology and Hematology,Zhengzhou the First Peoples Hospital,Zhengzhou 450004,China)

机构地区：[1]郑州市第一人民医院肿瘤血液科,河南郑州450004

出　　处：《医药论坛杂志》2022年第6期27-31,共5页Journal of Medical Forum

摘　　要：目的观察阿帕替尼联合托泊替康治疗晚期铂类耐药复发卵巢癌患者的临床疗效及安全性。方法选取郑州市第一人民医院2016年6月—2020年8月收治的52例晚期铂类耐药复发卵巢癌患者进行回顾性分析,分为观察组(26例,阿帕替尼联合托泊替康)与对照组(26例,单药托泊替康),评价两组的客观缓解率、疾病控制率、肿瘤标记物水平、无进展生存期、总生存期和不良反应发生率。结果观察组的客观缓解率、疾病控制率分别为42.3%、73.1%,均高于对照组的15.4%、38.5%,差异具有统计学意义(P<0.05);治疗后观察组的CA125、CEA水平均低于对照组,差异具有统计学意义(P<0.05);观察组的中位无进展生存期、中位总生存期分别为5.9个月(95%CI:4.1~7.6)、9.8个月(95%CI:6.9~12.7),均高于对照组的3.4个月(95%CI:2.7~4.0)、6.2个月(95%CI:4.9~7.5),差异具有统计学意义(P<0.05)。两组患者的骨髓抑制、乏力、胃肠道反应的发生率比较差异无统计学意义(P>0.05),而观察组的高血压、手足综合征及蛋白尿的发生率高于对照组,差异具有统计学意义(P<0.05),但3~4级不良反应少见,经减量及对症治疗后不良反应可缓解,总体耐受性良好。结论阿帕替尼联合托泊替康治疗晚期铂类耐药复发卵巢癌患者具有良好的临床疗效,可延缓疾病进展,延长生存期,且耐受性良好。Objective To observe the clinical efficacy and safety of apatinib combined with topotecan in the treatment of patients with advanced platinum-resistant relapsed ovarian cancer.Methods A retrospective analysis of 52 patients with advanced platinum-resistant relapsed ovarian cancer admitted to our hospital from June 2016 to August 2020 were divided into observation group(26 cases,apatinib combined with topotecan)and control group Group(26 cases,single-agent topotecan),evaluate the objective remission rate,disease control rate,tumor marker level,progression-free survival,overall survival,and incidence of adverse reactions in the two groups.Results The objective remission rate and disease control rate of the observation group were 42.3%and 73.1%,respectively,which were higher than 15.4%and 38.5%of the control group.The difference was statistically significant(P<0.05);The CA125 and CEA levels of the observation group after treatment All were lower than the control group,the difference was statistically significant(P<0.05);the median progression-free survival and median overall survival of the observation group were 5.9 months(95%CI:4.1-7.6)and 9.8 months,respectively(95%CI:6.9~12.7),higher than 3.4 months(95%CI:2.7~4.0)and 6.2 months(95%CI:4.9~7.5)of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of bone marrow suppression,fatigue,and gastrointestinal reactions between the two groups(P>0.05),while the incidence of hypertension,hand-foot syndrome and proteinuria in the observation group was higher than that in the control group.It is statistically significant(P<0.05),but grade 3-4 adverse reactions are rare,and the adverse reactions can be alleviated after dose reduction and symptomatic treatment,and the overall tolerance is good.Conclusion Apatinib combined with topotecan has a good clinical effect in the treatment of patients with advanced platinum-resistant relapsed ovarian cancer,which can delay disease progression,prolong survival,and is

关 键 词：卵巢癌 铂耐药 阿帕替尼 托泊替康 

分 类 号：R737.31[医药卫生—肿瘤]